Table 1 Summary of the randomized controlled trials on long-term macrolide administration in children with non-cystic fibrosis bronchiectasis.
From: Long-term macrolide treatment for non-cystic fibrosis bronchiectasis in children: a meta-analysis
Study | Characteristics | Intervention and study duration | Outcome | ||||
|---|---|---|---|---|---|---|---|
Country | Year | Number of subjects; mean age of experiment group, y | Number of subjects; mean age of control group, y | Experimental group | Control group | ||
Koh, 1997 | South Korea | 1995–1996 | 13; 13.3 ± 2.5 | 12; 12.9 ± 2.6 | Roxithromycin 4 mg/kg twice a day for 12 weeks | Placebo for 12 weeks | FEV1, PD20, exacerbation, sputum purulence score, sputum leukocyte score |
Masekela, 2013 | South Africa | 2009–2011 | 17; 8.4 ± 2.4 | 14; 9.1 ± 2.1 | Erythromycin 125 mg (≤ 15 kg), 250 mg (> 15 kg) once a day for 52 weeks | Placebo group for 52 weeks | Number of exacerbations, PFT (FEV1, FVC), cytokines |
Valery, 2013 | Australia | 2008–2010 | 45; 3.99 ± 2.14 | 44; 4.22 ± 2.3 | Azithromycin (30 mg/kg) once a week for up to 24 months | Placebo once a week for up to 24 months | Exacerbation rate (respiratory episodes treated with antibiotics) |
Yalcin, 2006 | Turkey | 1999–2000 | 17; 13.1 ± 2.7 | 17; 11.9 ± 2.9 | Clarithromycin 15 mg/kg, once daily with supportive therapies (mucolytic and expectorant medications, postural drainage) for 3 months | Supportive therapies (mucolytic and expectorant medications, postural drainage) for 3 months | Sputum production, PFT (FEF 25–75%), cytokines and culture using BAL fluids |
